Business Context and Reporting Period
This Form 8-K was filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on January 19, 2021. The filing discloses the approval of 2021 corporate objectives and bonus structures for executive officers by the Compensation Committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
| Executive Officer | 2020 Bonus Payout | 2021 Target Bonus Percentage |
|---|---|---|
| Casey C. Lynch (CEO) | $262,500 | 55% |
| Christopher Lowe (CFO) | $156,000 | 40% |
| Michael Detke, M.D., Ph.D. (CMO) | $164,000 | 40% |
| Stephen S. Dominy, M.D. (CSO) | $156,000 | 40% |
Material Changes
The filing details the establishment of 2021 performance goals, which differ from prior periods by explicitly linking bonuses to specific clinical and operational milestones. No financial performance changes are reported in this document.
Guidance, Outlook, and Risks
2021 Corporate Goals: Bonuses are contingent on achieving milestones in the following areas:
- GAIN trial and clinical execution/engagement.
- Other ongoing clinical trials and pipeline opportunities.
- Preclinical and chemical, manufacturing, and control (CMC) development.
- Operating plan and corporate governance/compliance.
- Market development and engagement.
- Commercialization planning.
Compensation Structure: Actual bonuses may exceed 100% of the target percentage if performance exceeds goals. Final payment amounts are at the discretion of the Committee or Board.
Investor Verification Checklist
- Verify the registrant name is Cortexyme, Inc. (CRTX), not Quince Therapeutics.
- Confirm the status of the GAIN trial and other clinical milestones listed as bonus criteria.
- Review the company's operating plan to assess the feasibility of the 2021 commercialization and CMC goals.
- Note that the filing does not contain audited financial statements or liquidity data.